PSS12 COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB AND RANIBIZUMAB IN NEOVASCULARAGE-RELATED MACULAR DEGENERATION (AMD)- A CLINICAL AND ECONOMIC COMPARISON OF TWO VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR TREATMENTS
Abstract
Authors
JJ Patel MA Stull M Bounthavong MLD Christopher E Foster AP Morreale BK Plowman DT Boggie